NetworkNewsBreaks – Pivot Pharmaceuticals Inc. (
Post# of 52
(Total Views: 239)
Posted On: 05/11/2018 4:07:27 PM
NetworkNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Leverages Innovative Technologies for Improved Cannabinoid Product Delivery
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) holds significant patents and a cannabinoid product portfolio designed with disruptive technologies that strive to maximize bioavailability, stability and drug release rates. A recent article highlights PVOTF’s innovative delivery technologies, indicating, “Some patents maintain the company’s impetus in making cannabis available through powdered formulations that can be combined with products in the food and beverage market. Through subsidiary Thrudermic (http://nnw.fm/AiZ6a), the company is invested in a transdermal lipid-based nano-dispersion technology that enhances skin absorption of cannabinoids, and the company’s water soluble, oral delivery product, PGS-N001, is designed to provide relief to cancer patients suffering from chemotherapy-induced vomiting, nausea, neutropenia and anemia by utilizing a bioavailability technology already demonstrated in Europe.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) holds significant patents and a cannabinoid product portfolio designed with disruptive technologies that strive to maximize bioavailability, stability and drug release rates. A recent article highlights PVOTF’s innovative delivery technologies, indicating, “Some patents maintain the company’s impetus in making cannabis available through powdered formulations that can be combined with products in the food and beverage market. Through subsidiary Thrudermic (http://nnw.fm/AiZ6a), the company is invested in a transdermal lipid-based nano-dispersion technology that enhances skin absorption of cannabinoids, and the company’s water soluble, oral delivery product, PGS-N001, is designed to provide relief to cancer patients suffering from chemotherapy-induced vomiting, nausea, neutropenia and anemia by utilizing a bioavailability technology already demonstrated in Europe.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)